Your session is about to expire
← Back to Search
uEXPLORER/mCT for Coronavirus
N/A
Waitlist Available
Led By Guobao Wang, PhD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
COVID-19 positive patients will have a previous positive COVID-19 test and radiographic findings, and/or a positive SARS-CoV-2 antibody test and be in early recovery.
First PET/CT visit needs to be within 8 weeks of COVID-19 diagnosis.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 imaging visit up to 60 minutes
Awards & highlights
Study Summary
This trial is comparing COVID-19 patients to normal subjects, and measuring changes over time.
Eligible Conditions
- Coronavirus
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 imaging visit up to 60 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 imaging visit up to 60 minutes
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
BAB permeability assessed
Secondary outcome measures
4 month follow-up PET/CT scan
Trial Design
1Treatment groups
Experimental Treatment
Group I: COVID-19 patientsExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
uEXPLORER/mCT
2021
N/A
~20
Find a Location
Who is running the clinical trial?
University of California, DavisLead Sponsor
908 Previous Clinical Trials
4,704,102 Total Patients Enrolled
Guobao Wang, PhDPrincipal InvestigatorUniversity of California, Davis
2 Previous Clinical Trials
71 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger